1. Pink Sheet
  2. >>Product Reviews

Keeping Track: 2021’s First Novel Approvals Go To HIV And Heart Failure Therapies Opdivo Starts Year With A Bang

 
• By Bridget Silverman

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

Merck & Co., Inc.’s Verquvo (vericiguat) became the first novel agent of 2021 when the US FDA approved the soluble guanylate cyclase stimulator for use in chronic heart failure patients with reduced ejection fraction on 19 January. Verquvo was joined just two days later by the second novel agent of the year, ViiV Healthcare’s antiretroviral cabotegravir, approved for HIV in two formulations as Cabenuva and Vocabria.

Bristol Myers Squibb Company’s blockbuster PD-1 inhibitor Opdivo (nivolumab) added a new renal cell carcinoma indication in combination with Exelixis, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

Smoldering Myeloma Endpoint Questions Carry J&J’s Darzalex Faspro To US FDA AdComm

 
• By Bridget Silverman

The US FDA seeks advice on the clinical meaningfulness of the endpoints of J&J’s AQUILA trial in smoldering multiple myeloma, highlighting the pitfalls of being the first candidate for the precancerous condition.

US FDA Adcomm To Consider If Genentech’s Columvi Study Generalizable To US

 
• By Sue Sutter

Patients from Asia saw a differential treatment effect versus non-Asian regions in the Phase III multiregional study, with an adverse survival trend seen in the latter group, the FDA said about the lymphoma drug.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.